Sun Pharma Continues to Retain No 1 Position in IPM for November: Pharmarack

“The Indian Pharmaceutical Market (IPM) posted solid growth in MAT Nov’25, reaching Rs 238,968 crore with an 8.0 per cent value increase, while monthly performance for Nov’25 recorded Rs 21,182 crore, reflecting a 9.1 per cent rise,” said Sheetal Sapale, Vice President (Commercial), Pharmarack Technologies.

In a presentation for IPM for November she said “Sun Pharma strengthened its dominant leadership position, achieving the No. 1 rank with exceptional double-digit growth of 11.8 per cent in MAT and an even higher 14.8 per cent growth in monthly sales. This sustained momentum underscores Sun Pharma’s strategic depth, strong portfolio performance, and continued market penetration across key therapeutic segments. Sun Pharma continues to reinforce its leadership with consistent double-digit expansion across both MAT and monthly metrics, further widening its lead over competitors.”

She further said “Abbott and Mankind secured the second and third positions, respectively, each demonstrating resilient growth supported by diversified product portfolios and stable demand trends. Cipla followed closely in fourth place, delivering strong double-digit monthly growth driven by both value and unit expansion. Alkem, Intas, Torrent, Lupin, and Zydus also contributed significantly to overall market acceleration, reflecting healthy competition within the top tier of the industry.”

While several companies, such as GSK and Pfizer, witnessed moderated or negative unit growth, their value performance remained steady within the top 20 rankings. The broader trends highlight a stable yet competitive market environment where leading corporates are leveraging innovation, field strength, and portfolio optimisation to drive performance.